The PDCD2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line. This product provides a heterogeneous pool of PDCD2-disrupted cells for loss-of-function studies in a lymphoma-relevant background. The polyclonal format avoids clonal selection bias, capturing diverse editing outcomes that collectively ablate PDCD2 function. Researchers can use these cells to investigate PDCD2??s role in apoptosis, cell cycle control, and transcriptional repression.
The Raji cell line originates from a human Burkitt??s lymphoma and retains characteristics of germinal center B cells. Widely used in immunology and oncology research, Raji cells express B cell surface markers and are sensitive to extrinsic apoptotic signals. This malignant B cell context is ideal for examining PDCD2??s tumor-suppressive functions, as the line harbors deregulated pathways relevant to lymphomagenesis. The EBV-positive status of Raji cells further permits studies of virus-host regulatory interactions.
PDCD2 acts downstream of the tumor suppressor p53 (TP53) as a transcriptional repressor. It forms homodimers and interacts with BCL6 to modulate apoptosis and cell cycle arrest. The p53-PDCD2-BCL6 axis converges on downstream effectors such as BAX and CDKN1A (p21), influencing cell survival and proliferation. PDCD2-mediated transcriptional repression is a key mechanism in p53-dependent responses. Disruption of PDCD2 in Raji cells allows dissection of this signaling node and its impact on B cell fate.
In B lymphocytes, PDCD2 is implicated in germinal center homeostasis, where tight control of proliferation and apoptosis prevents lymphomagenesis. The Raji background, with its Burkitt lymphoma origin, provides a model to study how PDCD2 loss disrupts these processes. BCL6 is frequently dysregulated in B cell malignancies, making the interplay between p53, PDCD2, and BCL6 particularly relevant. These polyclonal knockout cells help reveal PDCD2??s contribution to maintaining B cell genomic integrity and suppressing malignant transformation.
Applications include apoptosis assays (Annexin V flow cytometry), cell cycle analysis, and Western blotting for pathway components. Co-immunoprecipitation can assess PDCD2-BCL6 binding, while RT-qPCR and RNA-seq enable transcriptome-wide profiling. Drug sensitivity screening with chemotherapeutics or BCL6 inhibitors can test PDCD2-dependent therapeutic responses. These cells also serve in functional complementation and germinal center research. For further details, please contact Ascent Research.
